CRISPR Makes Prostate Cancer Vulnerable to Immunotherapy Researchers at the University of Rochester Medicine have made a significant breakthrough in using CRISPR technology to combat prostate cancer.
They successfully used a CRISPR based tool to make prostate tumors more vulnerable to immunotherapy, which helps the immune system identify and destroy cancer cells.
Most prostate tumors are "immune cold," meaning they attract very few T cells, a type of immune cell. This limits the effectiveness of immunotherapy in these cases.